Every 424B that Vor Biopharma Inc. (VOR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.
Vor Biopharma Inc. has filed a resale prospectus covering up to 13,876,032 shares of common stock previously issued in a December 18, 2025 private placement. These shares were sold to accredited investors at $10.81 per share for gross proceeds of $150 million.
The company is a clinical-stage biopharmaceutical business developing telitacicept for autoimmune diseases, including a global Phase 3 trial in generalized myasthenia gravis. Only the selling stockholders will receive proceeds from any share sales; Vor will cover registration costs but not selling expenses. The filing warns that large resales could pressure the stock price and notes that prior audited financial statements included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Vor Biopharma (VOR) launched a primary offering of 10,000,000 shares of common stock at $10.00 per share, a follow-on under its shelf registration. The deal includes a 30‑day option for underwriters to purchase up to 1,500,000 additional shares. The pricing table lists a public offering price of $10.00, underwriting discounts of $0.60 per share, and proceeds to the company of $9.40 per share before expenses. Vor estimates net proceeds of approximately $93.7 million after fees and expenses.
The company plans to use proceeds to advance telitacicept, including a Phase 3 trial in primary Sjögren’s disease, plus manufacturing, pre‑commercialization, working capital and general corporate purposes. Vor noted it is an emerging growth and smaller reporting company and completed a 1‑for‑20 reverse stock split on September 18, 2025. The company agreed to a 60‑day lock‑up (90 days for directors, officers and certain stockholders) and to pause sales under its ATM program for 30 days unless the underwriters’ option is exercised in full.
Vor Biopharma (VOR) launched a primary offering of $100,000,000 of common stock, with underwriters granted a 30‑day option to purchase up to an additional $15,000,000 of shares. The company’s stock trades on Nasdaq as “VOR.” On November 7, 2025, the last reported sale price was $18.70 per share. All share figures reflect the 1‑for‑20 reverse split effected on September 18, 2025.
Vor plans to use net proceeds to advance telitacicept, including a Phase 3 trial in primary Sjögren’s disease, manufacturing and pre‑commercialization activities, and for working capital and general corporate purposes. The company and certain insiders agreed to lock‑ups (company 60 days; directors, officers and certain stockholders 90 days). Vor also agreed not to sell under its ATM program for 30 days after this offering unless the underwriters’ option is exercised in full.
Shares outstanding were 6,282,297 as of June 30, 2025. This figure provides a baseline and is separate from the amount being offered.